Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

clan Mar. 13 at 11:31 PM

$MNKD We know Cipla $CIPLA.NSE has a DPI facility in NY (for Indian Afrezza[?]). Will B.I. build their own DPI facility, or will Mannkind make all the TechnOFEV in Danbury? $MRK $JNJ

0 · Reply

DragonAlgo Mar. 13 at 11:08 PM

🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-03-27 | Strike: $242.50 | Type: PUT Option Plan (premium): Entry: $5.75 Stop: $4.14 TP1: $7.48 TP2: $9.78 TP3: $13.80 🔗 https://dragonalgo.com

0 · Reply

SPY700baby Mar. 13 at 10:25 PM

$SYK hahahahahaha new SEC filing just hit they saying all operations day to day is DOWN and zero light at end of the tunnel… REMEMBER they wiped everything deleted boom gone !! you can’t restore shit !!! THIS IS 2026 doomsday and honestly couldn’t have happened to a worse medical device company that screws patients over ! $SPY $MDT $JNJ $ZBH hahahahahahahahahaha

0 · Reply

mikesterz7 Mar. 13 at 6:25 PM

$JNJ 🚨 🚨 🚨 Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results The study also demonstrated complete and durable responses in patients with recurrent intermediate-risk disease, along with encouraging recurrence-free outcomes in high-risk disease.

0 · Reply

StocktwitsNews Mar. 13 at 6:23 PM

Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results $JNJ $VTI $VOO https://stocktwits.com/news/equity/markets/johnson-and-johnson-trial-in-early-stage-bladder-cancer-yield-positive-safety-results/cZdDZJGRIOe

0 · Reply

kb60521 Mar. 13 at 4:56 PM

$JNJ No more closing at 240 today???

0 · Reply

StockNews_Live Mar. 13 at 4:36 PM

$JNJ 🎯 STOCK NEWS ALERT 💵 Price: $243.19 (+0.46%) 🔥 Sentiment Score: 92/100 🚀 VERY POSITIVE NEWS 📄 Johnson & Johnson announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with… 📎 https://stocknews.live/news/JNJ/johnson-johnson-highlights-promising-43744.html

0 · Reply

Moneyriver Mar. 13 at 4:10 PM

$JNJ horrible company this stock price will fall

0 · Reply

Quantumup Mar. 13 at 1:15 PM

Stifel⬆️ $ORKA's PT to $72 from $47 and reitertaed at Buy. $ABBV $JNJ - $PTGX $UCBJY Stifel said—ORKA now expects Ph2 psoriasis data from ORKA-001 in 2Q26 (from 2H26) -- enrollment completed December 2025. ORKA plans to share week-16 data while providing longer-term follow-up in 2H26 -- the prior guidance was to share both together. Bottom line, this update significantly moves up the timing of ORKA's first clinical readout, and we expect to see shares react favorably towards increased proximity to the update. In terms of bar for success, we think PASI100 rates in-line with Skyrizi (36-51%) would represent a win with potential for Q6M or yearly vs. Q3M dosing while we see prospective support for the exposure hypothesis from the KNOCKOUT study providing additional support for the upside hypothesis of Bimzelx-like responses (59%-68%). We see Base Case upside in the $50-$70 range; downside for inferior efficacy could see shares trade to $10-20 with a refocus towards ORKA-002.

0 · Reply

DragonAlgo Mar. 13 at 7:40 AM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-03-13 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $1.25 Stop: $0.90 TP1: $1.62 TP2: $2.12 TP3: $3.00 🔗 https://dragonalgo.com

0 · Reply

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 1 day ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 11, 2026, 9:36 AM EDT - 2 days ago

Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity

AMD APD CAT DHI FISV LLY

Mar 10, 2026, 5:10 PM EDT - 3 days ago

Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 8 days ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 8 days ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 9 days ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 2:02 PM EST - 10 days ago

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 1:18 PM EST - 10 days ago

Wasatch Global Value Fund Q4 2025 Performance Review

BABA C T VICI

Mar 3, 2026, 8:03 AM EST - 10 days ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 11 days ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 27, 2026, 12:21 PM EST - 14 days ago

Best Dividend Aristocrats For March 2026

ABBV ABT ADM ADP AFL ALB AMCR

Feb 26, 2026, 5:34 PM EST - 15 days ago

2 Dividend Kings That Could Easily Keep The Growth Streak Alive

AWR DOV GPC PG

Feb 26, 2026, 2:30 PM EST - 15 days ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 17 days ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 18 days ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 18 days ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 18 days ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 20 days ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:30 PM EST - 22 days ago

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

Feb 19, 2026, 5:00 PM EST - 22 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 22 days ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 22 days ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 9:15 AM EST - 22 days ago

2 High-Yield CEFs To Enhance Your Retirement Income

AMLP ASGI BIZD BTI MO SCHD T

Feb 18, 2026, 10:44 AM EST - 23 days ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 23 days ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 23 days ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 23 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 24 days ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 6:23 AM EST - 24 days ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM LYB MCD

Feb 13, 2026, 4:19 PM EST - 4 weeks ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 4 weeks ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 4 weeks ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 4 weeks ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 4 weeks ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 4 weeks ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 5 weeks ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 5 weeks ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 5 weeks ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 5 weeks ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 5 weeks ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 5 weeks ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 1, 2026, 10:35 AM EST - 5 weeks ago

Ariel Focus Fund Q4 2025 Portfolio Review

ADT AMG B FISV MOS ORCL

Jan 30, 2026, 2:43 PM EST - 6 weeks ago

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Jan 30, 2026, 7:19 AM EST - 6 weeks ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 6 weeks ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 6 weeks ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 28, 2026, 9:38 AM EST - 6 weeks ago

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 27, 2026, 3:49 PM EST - 6 weeks ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 6 weeks ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

clan Mar. 13 at 11:31 PM

$MNKD We know Cipla $CIPLA.NSE has a DPI facility in NY (for Indian Afrezza[?]). Will B.I. build their own DPI facility, or will Mannkind make all the TechnOFEV in Danbury? $MRK $JNJ

0 · Reply

DragonAlgo Mar. 13 at 11:08 PM

0 · Reply

SPY700baby Mar. 13 at 10:25 PM

0 · Reply

mikesterz7 Mar. 13 at 6:25 PM

0 · Reply

StocktwitsNews Mar. 13 at 6:23 PM

0 · Reply

kb60521 Mar. 13 at 4:56 PM

$JNJ No more closing at 240 today???

0 · Reply

StockNews_Live Mar. 13 at 4:36 PM

0 · Reply

Moneyriver Mar. 13 at 4:10 PM

$JNJ horrible company this stock price will fall

0 · Reply

Quantumup Mar. 13 at 1:15 PM

0 · Reply

DragonAlgo Mar. 13 at 7:40 AM

0 · Reply

jewell69 Mar. 12 at 10:01 PM

$JNJ $MOS caught just 2 of the fast money final trades 3/12

1 · Reply

truehealthvalue Mar. 12 at 9:23 PM

$JNJ take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position

0 · Reply

DragonAlgo Mar. 12 at 7:22 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-03-20 | Strike: $245.00 | Type: CALL Option Plan (premium): Entry: $3.25 Stop: $2.34 TP1: $4.23 TP2: $5.52 TP3: $7.80 🔗 https://dragonalgo.com

0 · Reply

Tigerpicko Mar. 12 at 6:08 PM

$LEGN Options setup is screaming bullish 📊 March 20 chain showing • 1,112 calls stacked at $20 • Heavy upside positioning at $22.5 and $25 • Puts mostly far below price Market makers are sitting on a gamma magnet at $20. With Carvykti sales ramping and analysts reiterating Overweight, a break over $20 could trigger a fast move. Targets: 🎯 $22.50 🎯 $25 🎯 $30 if squeeze builds $LEGN $JNJ

0 · Reply

IndyOne Mar. 12 at 5:11 PM

$MRNA Moderna’s mRNA 4157 (V940) combined with Keytruda delivered a durable 49% reduction in recurrence or death for Phase 2b melanoma results. Merck’s Keytruda pulled $31.7B in 2025 revenue. Keytruda’s patent clock is ticking and Merck can extend with mRNA-4157. The 49% RFS benefit holding at 5 years is rare in oncology. Most immunotherapy benefits erode over time. This one didn't. The 62% DMFS reduction is actually the stronger number and it's underreported. Follow the bread crumbs that show news coming on large partnership or buyout $JNJ $MRK $ABBV Will J&J, Merck, or AbbVie make the next move on Moderna's platform? Buy Moderna and hold. Then buy some more.

1 · Reply

ZacksResearch Mar. 12 at 4:21 PM

$BMY’s pipeline is deep and promising — are you ready for the upside? 🚀 💊 Positive phase III SUCCESSOR-2 study for mezigdomide in RRMM 🤝 Milvexian partnership with $JNJ to redefine anticoagulant therapy 🔍 Valuation: Trading at 9.64x forward earnings vs. industry’s 17.99x Opportunity assessment here 👉 https://www.zacks.com/stock/news/2883253/is-bristol-myers-deep-pipeline-the-key-to-future-growth?cid=sm-stocktwits-2-2883253-body-37176&ADID=SYND_STOCKTWITS_TWEET_2_2883253_BODY_37176

0 · Reply

JJBurch Mar. 12 at 4:07 PM

$OSRH 🚨 🚨 🚨 THE RUN IS STARTING RIGHT NOW! $815M licensing agreement with $30M upfront ready and due to be announced at ANY MOMENT but no later than May I expect it IMMINENTLY hurry. Grab it right now as it starts its huge run Congrats to all!!! Massive winner. $10 price target JUST GIVEN weeks ago. Whew. $IXHL $JNJ $PLTR $TSLA

2 · Reply

triplea12 Mar. 12 at 4:03 PM

$IXHL $JNJ $OSRH $PLTR $TSLA damn what happened in 30mins for you to change your mind? 🤣🤡💩 when you see JJBurch it’s time to sell the stock

0 · Reply

JJBurch Mar. 12 at 4:01 PM

$IXHL took the L here. All out And doubled my position at .50 for an ALL IN at $OSRH .50 with a $10 short term price target and $815M licensing deal with definitive binding terms ready for signatures. Good luck everyone!! $TSLA $PLTR $JNJ

0 · Reply

AStrokeOfLuck Mar. 12 at 12:34 PM

$JNJ

0 · Reply

Tigerpicko Mar. 12 at 10:11 AM

$LEGN 🚀 Calls $22.5–$25 heating up, almost no puts → minimal downside, shorts trapped 💣 Analysts targets $62–$86! Carvykti + $JNJ driving explosive growth. Low $20S now → $25–$30 next! Momentum incoming 💥 $LEGN $JN

0 · Reply

Tigerpicko Mar. 12 at 9:57 AM

$LEGN 🚀💥 CAR‑T Carvykti booming with $JNJ backing! Analysts targets $62–$86, low $20S now → huge upside potential. Calls $22.5–$25 heating up, shorts still trapped 💣 Momentum could ignite fast! $LEGN $JNJ $BULLISH.X $STOCKTWITS

0 · Reply

Market Cap	583.29B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.50
Forward PE	21.06
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	6,415,500
Avg Vol	9,007,718
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	49%
Beta	0.34
Analysts	Strong Sell
Price Target	$240.48